PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Polymorphisms in PNPLA3 and TM6SF2 (i.e. PNPLA3 rs738409 c.444 C > G p.I148M and TM6SF2 rs58542926 C > T E167K) may potentially provide further insight into informing us why NAFLD might act to increase risk of CVD and also why there is the heterogeneity of CVD risk in patients with NAFLD.